UA-38958768-1
Your browser version is outdated. We recommend that you update your browser to the latest version.

Epidural Steroid Injections

Posted 11/18/2013

Epidural $teroid Injections: Are the long term risks worth the short term benefits?

Outpatient “procedures” are where the money is in medicine these days.  Procedures are invasive treatments that are not quite surgery, but are not conservative care either.   Non-surgical “procedurists” are falling over themselves to learn these lucrative businesses at an alarming rate. This is true in several medical specialties:  Cardiac catheterization labs, GI endoscopies and colonoscopies, interventional radiology procedures, PMR pain procedures, urologic cystoscopies, chiropractic manipulation under anesthesia, epidural steroid injection therapies and many other pain procedures.  If utilized correctly, these procedures may be valuable tools in the treatment of patients by preventing more invasive procedures, and in the case of cystoscopies and colonoscopies, aid in the early detection of cancer.

Procedures can be done quickly with assembly line efficiency and are very profitable for the physician.   In the case of epidural steroid injections, a ten minute epidural procedure will generally yield anywhere from a couple hundred to a couple thousand dollars, though I have heard of a series of three epidurals going for as much as $8,000.  Furthermore, if done in an outpatient facility, the physician does not have to split the fees with a hospital and the insurance company does not need to pay the higher costs that normally accompany hospital-based procedures.  Last year in the United States, the Centers for Medicare/Medicaid Services (CMS) paid for nearly nine million epidural steroid injections.  This number may not appear surprising at first, but when you consider that ESI therapies are neither approved by the FDA (1) nor recommended by the manufacturers (2) due to reports of severe adverse events, it becomes alarmingly relevant!  Note that the CMS number is not the total number of ESIs performed in the United States.  The nine million number represents only those ESIs paid for by CMS.  When we add in the number of ESI performed in the DOD, VA, workers compensation systems, and private insurances that number could conceivably be in the tens of millions. 

While is it true that epidural steroid injections (ESI) are not FDA approved, Medicare, Medicaid, workers compensation, and most other insurers continue to pay hundreds of millions of dollars per year for this controversial procedure.   Ironically on every vial of Kenalog (a popular steroid used for epidural injections) there is actually a warning against its use for epidural injections, yet “procedurists” still continue to use it. 

Although there is inadequate evidence to support the high use of ESI usage in the United States, it remains a very popular growth industry.  This is partially due to ESI being purported to reduce the number of spine surgeries.   However studies like one performed by Arden, et al. (2) showed that ESI did not offer sustained benefits nor did they reduce the need for spinal surgery.  Arden’s study did show that there was a transient reduction of symptoms of patients with sciatica.  Carette, et al. performed a separate study with similar results. (3)

In the ten year period between 2000 and 2010 the use of ESI increased 160%.   Dr. Manchikanti, Chairman of the American Society of Interventional Pain Physicians, stated, "We are doing too many of these (spinal injections), and many of those don't meet the proper criteria."(4)  He attributed this remarkable increase in spinal injections to the increased number of patients seeking pain relief and the financial incentives afforded to the treating physicians. 

The over-utilization of this profitable model of care is out of control and in my opinion is the next healthcare bubble growing at such an alarming pace it can only result in a burst.  When it does burst, these physicians will scramble to the next profit-driven model of care.  My hope is that the next profit model will be based on value of care versus quantity of care. 

epidural injectionepidural injection

Figure 1.Epidural Injection illustration by Bruce Blaus.

Used with permission: http://commons.wikimedia.org/wiki/User:BruceBlaus

Risks of ESI

While major damage associated with ESI is rare according to the literature, we are seeing a surge in the total number of patients with complications like chemical meningitis and adhesive arachnoiditis (which I personally feel is under reported).  Even if these complications are rare, when nine million ESIs are performed annually, we are going to see more adverse effects.  In my 28 years in practice I have seen two patients who became quadriplegics after receiving cervical ESI, one MS patient confined to a wheelchair after receiving an epidural, another with vertebral body osteomyelitis when he received an epidural the day after dental surgery, and another with adhesive arachnoiditis following an ESI.  Five severe complications from ESI in a lifetime of practice is not very high, but did the perceived benefit of this procedure justify the risk?

Note that I did not even mention the fungal meningitis outbreak that killed and maimed hundreds of patients who received tainted ESI in 2012. (5)  That tragic epidemic would warrant its own article.

As with any treatment the perceived benefit should be balanced by the risk, with the right doctor doing the right procedure on the right patient.  The perceived benefit for ESI does not substantiate its current level of utilization.  A common misconception in referring patients for ESI is that this procedure may reduce the need for surgery.  In fact the science clearly indicates that ESI therapies do not reduce the need for surgery and is only effective in providing temporary short-term pain relief.  Are the serious risks worth the short term benefits?

Hope

As healthcare reimbursement shifts from fee-for-service to reimbursement based on the value of care, we can hope to see the glut of medical procedures come under greater scrutiny and be subject to review and control.  

(1)   Epstein NE. The risks of epidural and transforaminal steroid injections in the spine: Commentary and a comprehensive review of the literature. Surg Neurol Int. 2013; 4(Suppl 2): S74–S93.

(2)   Methylprednisolone Acetate/DepoMedrol Reformulation/Epidural Use. Pharmacia Upjohn/Pfizer, New York, NY.

(3)   Arden NK, Price C, Reading I, Stubbing J, Hazelgrove J, Dunne C, et al. A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: The WEST study. Rheumatology (Oxford).  2005; 44:1399-406.

(4)   Carette S, Leclaire R, Marcoux S, Morin F, Blaise GA, St-Pierre A, et al. Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. N Engl J Med 1997;336:1634-40.

(5)   Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Fellows B. Complications of fluoroscopically directed facet joint nerve blocks: A prospective evaluation of 7,500 episodes with 43,000 nerve blocks. Pain Physician 2012;15:E143-50. 

(6)   American Medical Association Morning Rounds, in Affiliation with Bulleting HEALTHCARE, CDC: 25 dead in meningitis outbreak, cases reach 337 in 18 states. Monday, October 29, 2012.